Loading...
01/11 08:24
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary and Q&A session indicate positive financial metrics, such as raised guidance for revenue, EBITDA, and EPS for 2025, and strong free cash flow expectations. The company is expanding capacity with new projects and partnerships, and AI is enhancing operations. While there are concerns about management's clarity on certain issues, the overall sentiment is positive, especially with raised guidance and expansion plans. The market strategy and shareholder return plans are also favorable, suggesting a positive stock price movement.
Revenue Revenue for the second quarter increased 12% to $1.46 billion. The increase was driven by 7.2% discharge growth and a 4.2% increase in net revenue per discharge. The net revenue per discharge benefited from a decrease of 90 basis points in bad debt expense to 2%.
Adjusted EBITDA Adjusted EBITDA increased 17.2% to $308.6 million. This growth was supported by the revenue increase and operational efficiencies.
Discharge Growth Total discharges for Q2 increased 7.2%, including 4.7% in same-store discharges. This growth was broad-based across geographies, payers, and patient types.
Net Revenue Per Discharge Net revenue per discharge increased by 4.2%. This was partly due to a decrease in bad debt expense by 90 basis points to 2%.
Adjusted Free Cash Flow Adjusted free cash flow increased 30.5% to approximately $186 million for Q2, and year-to-date adjusted free cash flow increased 31.7% to approximately $408 million. This increase was attributed to strong operational performance and tax benefits from additional bonus depreciation.
Salaries and Wages Per FTE Salaries and wages per FTE, excluding contract labor and bonuses, increased 3.4%. Contract labor and bonuses declined by $4.9 million or 15.1%, and contract labor FTEs represented 1.3% of total FTEs.
Benefit Expense Per FTE Benefit expense per FTE increased by 18%, driven by an increase in the frequency of high-dollar medical claims.
Net Preopening and Ramp-Up Costs Net preopening and ramp-up costs were $4 million in Q2, with a first-half total of $6.1 million. These costs are expected to range between $18 million and $22 million for the full year.
Leverage and Liquidity Net leverage at quarter-end was 2x. The company ended the quarter with approximately $100 million in unrestricted cash and over $950 million available on a $1 billion revolving credit facility.
New hospital openings: Opened a new 60-bed hospital in Fort Myers, Florida, and a 50-bed hospital in Daytona Beach, Florida. Plans to open 5 additional hospitals (4 de novos with 190 beds and a 50-bed freestanding satellite hospital) and add 30-50 beds to existing hospitals in 2025.
Market demand: Demand for inpatient rehabilitation services is growing due to an aging U.S. population. The Medicare beneficiary population, the fastest-growing segment, is expected to reach 70 million by 2030.
Revenue growth: Revenue increased by 12% to $1.46 billion in Q2 2025, driven by 7.2% discharge growth and a 4.2% increase in net revenue per discharge.
Operational efficiencies: Contract labor and sign-on bonuses declined by $4.9 million (15.1%), and bad debt expense decreased to 2%.
Capital expenditure adjustments: Increased 2025 growth CapEx estimate by $25 million for bed expansions and $5 million for accelerated land purchases for future de novo hospitals.
Regulatory Developments: The company acknowledges risks related to regulatory developments, which could impact projections, estimates, and expectations. This includes the 2026 IRF final rule by CMS, which introduces a net market basket update of 2.6%.
Cost Trends: The company faces challenges with increasing benefit expenses, driven by a rise in high-dollar medical claims. Although this is expected to moderate in the second half of the year, it remains a concern.
Prepayment Claims Reviews: The company experienced significant increases in prepayment claims reviews under TPE in Q2 2024, which impacted bad debt expense. While this has improved, it remains a potential risk.
Labor Costs: Salaries and wages per FTE increased by 3.4%, and while contract labor costs have declined, labor expenses remain a critical area of focus.
Supply of Licensed IRF Beds: The demand for inpatient rehabilitation services is growing faster than the supply of licensed IRF beds, creating a potential bottleneck in meeting patient needs.
Preopening and Ramp-Up Costs: The company incurred $4 million in preopening and ramp-up costs in Q2, with full-year costs expected to range between $18 million and $22 million, which could impact financial performance.
2025 Guidance Update: Net operating revenue is projected to be between $5.88 billion and $5.98 billion. Adjusted EBITDA is expected to range from $1.22 billion to $1.25 billion. Adjusted earnings per share are forecasted to be between $5.12 and $5.34.
Medicare Revenue Impact: The 2026 IRF final rule includes a net market basket update of 2.6%, estimated to result in a 2.7% increase in net revenue per discharge for Medicare patients starting October 1, 2025.
Capital Expenditures: 2025 growth CapEx estimate has been increased by $25 million for bed expansions and $5 million for accelerated land purchases for future de novo projects. Total preopening and ramp-up costs for 2025 are expected to range from $18 million to $22 million.
Free Cash Flow: 2025 adjusted free cash flow is now expected to be between $705 million and $795 million, reflecting strong Q2 performance and tax benefits from additional bonus depreciation.
Hospital Expansion Plans: Plans to open 5 additional hospitals in 2025, including 4 de novos with a total of 190 beds and a 50-bed freestanding satellite hospital. An additional 30 to 50 beds will be added to existing hospitals.
Market Demand and Demographics: The demand for inpatient rehabilitation services is expected to grow as the U.S. population ages. By 2030, 1 in 5 Americans will be aged 65 or older, with the 75-plus population growing at approximately 4% annually.
Quarterly Dividend Increase: The company announced an increase in its quarterly dividend, which will be payable in October, to $0.19 per share.
Share Repurchase Program: During the second quarter, the company repurchased approximately 232,000 shares of its common stock for $24.7 million.
The earnings call summary and Q&A indicate positive sentiment: strong financial metrics, optimistic guidance, and strategic expansion plans. Despite a decrease in adjusted free cash flow, year-to-date growth is robust. The focus on bed expansion and reduced premium labor costs are favorable. However, management's lack of clarity on certain issues and the absence of a market cap metric slightly temper the outlook. Overall, the strategic initiatives and positive guidance suggest a stock price increase of 2% to 8% over the next two weeks.
The earnings call summary and Q&A session indicate positive financial metrics, such as raised guidance for revenue, EBITDA, and EPS for 2025, and strong free cash flow expectations. The company is expanding capacity with new projects and partnerships, and AI is enhancing operations. While there are concerns about management's clarity on certain issues, the overall sentiment is positive, especially with raised guidance and expansion plans. The market strategy and shareholder return plans are also favorable, suggesting a positive stock price movement.
The earnings call indicates strong financial performance with a 10.6% revenue increase and a 14.9% rise in adjusted EBITDA. Share repurchases and dividends further bolster shareholder confidence. The Q&A revealed management's proactive approach to potential risks like benefit expenses and supply costs, without significant concerns. Despite some uncertainties in future costs and trends, the optimistic guidance and strategic expansion plans, such as increased partnerships, suggest a positive outlook for stock price movement.
The earnings call presents strong financial performance with revenue and EBITDA growth, positive cash flow, and strategic positioning in a growing market. The Q&A section reveals management's confidence in labor efficiency and growth strategy, despite some uncertainties in regulatory and economic factors. The share repurchase and cash dividend enhance shareholder returns. The lack of specific guidance on some questions is a minor concern, but overall, the positive financial metrics and optimistic market positioning suggest a positive stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
